Literature DB >> 9636521

Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation.

G Morris-Stiff1, T Richards, J Singh, K Baboolal, V Balaji, K Ostrowski, R Moore, C Darby, R Lord, W A Jurewicz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9636521     DOI： 10.1016/s0041-1345(98)00243-7

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  6 in total

1.  Immunosuppression in renal transplantation. Meta-analysis should not have included one of the studies.

Authors:  G Morris-Stiff; A Khan; I Quiroga; R Baboo; W A Jurewicz
Journal:  BMJ       Date:  1999-10-23

2.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 3.  Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.

Authors:  A J Coukell; G L Plosker
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

Review 4.  Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

Authors:  C J Dunn; A J Wagstaff; C M Perry; G L Plosker; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Economic evaluations of calcineurin inhibitors in renal transplantation: a literature review.

Authors:  Alec H Miners; Guiqing Yao; James Raftery; Rod S Taylor
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.

Authors:  Michelle E Orme; Wieslaw A Jurewicz; Nagappan Kumar; Tracy L McKechnie
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.